BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 26749343)

  • 1. Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar.
    Awaisu A; Hamou F; Mekideche L; El Muabby N; Mahfouz A; Mohammed S; Saad A
    Int J Clin Pharm; 2016 Apr; 38(2):353-61. PubMed ID: 26749343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
    Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study.
    Lam AS; Yan BP; Lee VW
    BMJ Open; 2020 Dec; 10(12):e042229. PubMed ID: 33273050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The underutilisation of dual antiplatelet therapy in acute coronary syndrome.
    Anastasius M; Lau JK; Hyun K; D'Souza M; Patel A; Rankin J; Walters D; Juergens C; Aliprandi-Costa B; Yan AT; Goodman SG; Chew D; Brieger D
    Int J Cardiol; 2017 Aug; 240():30-36. PubMed ID: 28476519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
    Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
    Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
    Ho PM; Maddox TM; Wang L; Fihn SD; Jesse RL; Peterson ED; Rumsfeld JS
    JAMA; 2009 Mar; 301(9):937-44. PubMed ID: 19258584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
    Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
    Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton Pump Inhibitors and In-Hospital Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy.
    Zhou M; Zhang J; Liu J; Smith SC; Ma C; Ge J; Huo Y; Fonarow GC; Liu J; Hao Y; Gao F; Sun Y; Morgan L; Yang N; Hu G; Zeng Y; Han Y; Zhao D;
    Mayo Clin Proc; 2022 Apr; 97(4):682-692. PubMed ID: 35164933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and predictors of digoxin utilization among heart failure patients with reduced ejection fraction in Qatar.
    Rahhal AA; Awaisu A; Tawengi KM; AbuYousef S; Mekideche L
    Int J Clin Pharm; 2017 Oct; 39(5):1070-1083. PubMed ID: 28823072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.
    Ortolani P; Marino M; Marzocchi A; De Palma R; Branzi A
    J Cardiovasc Med (Hagerstown); 2012 Dec; 13(12):783-9. PubMed ID: 21252697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
    Vaduganathan M; Cannon CP; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Bhatt DL;
    Am J Med; 2016 Sep; 129(9):1002-5. PubMed ID: 27143321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving use of proton pump inhibitors with dual antiplatelet therapy in patients admitted with acute coronary syndrome.
    Jinadu T; Radhakrishnan A; Fan L
    BMJ Open Qual; 2022 Dec; 11(4):. PubMed ID: 36564103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation.
    Luinstra M; Naunton M; Peterson GM; Bereznicki L
    J Clin Pharm Ther; 2010 Apr; 35(2):213-7. PubMed ID: 20456741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review.
    Melloni C; Washam JB; Jones WS; Halim SA; Hasselblad V; Mayer SB; Heidenfelder BL; Dolor RJ
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):47-55. PubMed ID: 25587094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
    Ayub A; Parkash O; Naeem B; Murtaza D; Khan AH; Jafri W; Hamid S
    Indian J Gastroenterol; 2016 Mar; 35(2):117-22. PubMed ID: 27056735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK.
    Suh DC; Hunsche E; Shin HC; Mavros P
    Rheumatology (Oxford); 2008 Apr; 47(4):458-63. PubMed ID: 18263598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease.
    Khan SU; Lone AN; Asad ZUA; Rahman H; Khan MS; Saleem MA; Arshad A; Nawaz N; Sattur S; Kaluski E
    Cardiovasc Revasc Med; 2019 Dec; 20(12):1125-1133. PubMed ID: 30773427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.